BCAL Diagnostics Limited (ASX:BDX) Insider Acquires A$14,375.00 in Stock

BCAL Diagnostics Limited (ASX:BDX) insider Jayne Shaw purchased 125,000 shares of the business’s stock in a transaction on Friday, September 13th. The shares were purchased at an average price of A$0.12 ($0.08) per share, with a total value of A$14,375.00 ($9,712.84).

BCAL Diagnostics Stock Performance

The company has a quick ratio of 6.70, a current ratio of 3.60 and a debt-to-equity ratio of 17.74.

BCAL Diagnostics Company Profile

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body.